FDA Expands Indication for REVLIMID® (Lenalidomide) in Combination with Dexamethasone to Include Patients Newly Diagnosed with Multiple Myeloma

FDA Expands Indication for REVLIMID® (Lenalidomide) in Combination with Dexamethasone to Include Patients Newly Diagnosed with Multiple Myeloma